Sandoz Group AG Sponsored ADR (SDZNY)
(Delayed Data from OTC)
$55.96 USD
-0.82 (-1.44%)
Updated Aug 6, 2025 10:49 AM ET
3-Hold of 5 3
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
SDZNY 55.96 -0.82(-1.44%)
Will SDZNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SDZNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SDZNY
Zacks Industry Outlook Highlights Sandoz, Teva Pharmaceuticals and Viatris
3 Generic Drug Stocks to Watch Amid Pricing Pressure & Tariff Threats
SDZNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
SDZNY vs. STVN: Which Stock Should Value Investors Buy Now?
Zacks Industry Outlook Dr. Reddy's, Sandoz and Teva Pharmaceuticals
3 Generic Drug Stocks to Watch Amid Trade War Jitters & Inflation Woes
Other News for SDZNY
Bayer Stock Is Soaring Ahead Of Its Earnings Release
Sandoz signs non-binding term sheet with Evotec SE to acquire its Just-Evotec Biologics ...
Sandoz to acquire Just-Evotec Biologics from Evotec for $300M
Novartis fails in bid to block MSN Pharma’s generic Entresto as court denies injunction
Sandoz issues recall for additional lot of Cefazolin for injection